Kidney Failure, Chronic3SNCT02453412
Preoperative Arteriovenous Fistula Simulation Study (ShuntSimulationStudy)
A study testing AVF-simulation in people with Kidney Failure, Chronic and Arteriovenous Fistulae, run by Maastricht University Medical Center at 9 sites in Netherlands.
Trial summary
Patients suffering from end-stage renal disease (ESRD) are dependent on renal replacement therapy (dialysis). The majority of dialysis is facilitated by hemodialysis. For hemodialysis a vascular access is necessary, preferable an arteriovenous fistula (AVF) in which a vein is directly anastomosed to an artery. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Kidney Failure, Chronic, Arteriovenous Fistulae
- What is being tested?
- AVF-simulation
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 236 participants
- Where
- 9 sitesNetherlands
- Study dates
- May 2015to Jun 2019
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Incident patients that enter the pre-dialysis program because of end-stage renal failure and need for vascular access.
- Permanent dialysis patients in need of a new VA in the contralateral arm because of a previous failed access.
- Patients in which treatment of first choice is the creation of an autologous AVF.
- Patients with adequate arteries and veins (duplex) for creation of RC-, BC- or BBAVF.
- Patients that signed the written informed consent.
Who cannot join
- Patients with contraindications for creation of an autologous AVF (skin infection, ischemia, heart failure)
- Patients with a previous vascular access in the ipsilateral arm.
Trial locations and contacts
9 sites in 1 country.
9 sites in 1 country
Netherlands9 sites
Flevoziekenhuis
Almere Stad, Flevoland, 1315RA
Slingeland ziekenhuis
Doetinchem
Catharina ziekenhuis
Eindhoven
Zuyderland
Heerlen
Maastricht University Medical Center
Maastricht, 6229HX
St. Antonius ziekenhuis
Nieuwegein
Laurentius ziekenhuis
Roermond
Maasstad Ziekenhuis
Rotterdam, South Holland, 3079DZ
UMC Utrecht
Utrecht
About this study
Official title: Randomized-controlled Clinical Trial for the Evaluation of the Efficacy of Computational Simulation for the Planning of Vascular Access Surgery in Hemodialysis Patients
Patients suffering from end-stage renal disease (ESRD) are dependent on renal replacement therapy (dialysis). The majority of dialysis is facilitated by hemodialysis. For hemodialysis a vascular access is necessary, preferable an arteriovenous fistula (AVF) in which a vein is directly anastomosed to an artery. In order to use the AVF for hemodialysis three criteria have to be met; the minimal flow over the AVF is 600 mL/min, the diameter is at least 6 mm, and the AVF is located less than 6 mm under the skin. Unfortunately, approximately half of the patients (50%) are confronted with an AVF that does not meet these criteria; the so called non-maturation or primary failure. In case of non-maturation the AVF is not only unusable for dialysis, but also requires reinterventions on short- and long-term. Firstly to mature the AVF, and secondly, when the AVF is matured, to keep the vascular access. Using a computational simulation postoperative flow can be predicted. Based on patient-specific duplex measurements, the model can calculate the flow that can be expected following vascular access surgery for all AVF configurations; fore- or upper arm. These calculations lead to an advice which configuration is indicated; a flow that exceeds 600 mL/min, leading to maturation. Potentially the aforementioned 50% of non-maturation can be reduced. The patient then has an adequate vascular access and reinterventions are adverted, resulting in a decrease of costs, hospital demand, and an increase of the patients' quality of life. When the expected reduction of non-maturation is confirmed, the computational tool can be offered to other hospitals.
Read the detailed description
End-stage renal disease (ESRD) is a major and growing healthcare problem associated with substantial costs. By the end of 2010 the global patient population requiring chronic renal replacement therapy (RRT) exceeds 2 million, of which approximately 90% relies on hemodialysis (HD). The number of patients dependent on RRT are expected to annually increase with 8%. Based on this figure, it is expected that in 2030, 7.3 million ESRD patients need HD treatment. To facilitate adequate HD therapy a reliable vascular access (VA) is mandatory and can be provided by either creation of an autologous arteriovenous fistula (AVF), a prosthetic arteriovenous graft (AVG) or a central venous catheter (CVC). Guidelines by the National Kidney Foundation (NKF K/DOQI Guidelines), the Vascular Access Society (Good Nephrological Practice Guidelines) and the European Dialysis and Transplant Association (European Best Practice Guidelines on vascular access) advocate the implementation of an all-autologous fistula policy to maximize the use of AVF over AVG and CVC because AVF have the best long-term patency, fewer complications and require less interventions once fully maturated. Although the implementation of preoperative ultrasonography examination for vessel assessment has reduced the number of early AVF failure by improving the selection of the most suitable vessels and site for AVF creation, short- and long-term AVF dysfunction remains the major cause of morbidity and hospitalisation in HD patients, and is therefore the major limitation for HD treatment. This dysfunction is usually associated with non-maturation of the newly created AVF or the formation of neo-intimal hyperplasia (NIH) which potentially results in decreased access flow and eventual fistula thrombosis in up to 50% of AVFs. On the other hand, the low resistance vascular traject via the AVF may lead to impeded perfusion of the extremity distally of the AV anastomosis resulting in hand ischemia (HAIDI = Hemodialysis Access Induced Distal Ischemia), while an abundant AVF flow may lead to the development of left ventricular hypertrophy, both with potentially severe consequences. These high-flow complications occur in approximately 20% of fistulae. Numerous studies have investigated alternative preoperative mapping tools and criteria for reduction of AVF related complications. However, current clinical use of these individual tools and parameters does not take into account their potential interplay at a systemic level. Therefore one might consider that multiple prognostic parameters within a single patient are likely more valuable to improve outcome and therefore it is obvious to tailor the type of AVF to the individual patient. A possible solution to deal with multiple independent prognostic factors is implementation of a predictive patient-specific computational tool that relates geometrical, mechanical and hemodynamical parameters by means of physical laws. As a result, the computational tool takes the complex interplay between different prognostic parameters into consideration and accounts for individual differences in anatomy, physiology, demography and hemodynamics. Such an innovative computational tool opens new opportunities. By predicting postoperative flow abovementioned deleterious events can possibly be prevented. High-flow (>1500ml/min) and low-flow (<600ml/min) vascular access can then be predicted and consequently be rejected and a more suitable AVF-configuration chosen.
Consequently, simulation of outcome after AVF creation is at hand. Recently, the feasibility of VA computational simulation has been investigated and proven in the ARCH FP7 ICT-224390 project (ARCH; patient-specific image-based computational modeling for improvement of short- and long- term outcome of vascular access in patients on hemodialysis therapy). Within this technological and clinical study, longitudinal collection of cardiovascular data was performed with the intention to develop, calibrate and validate patient-specific modelling tools for surgical planning and assistance in the management of complications arising from AVF creation. Given the difficult and heterogeneous patient population, the study protocol was designed in such way that pre- and postoperative imaging could be performed strictly, aiming at complete datasets of structural, functional and demographical data. Although the computational simulation model has been validated in a small patient group, larger randomized observational patient studies, aiming at evaluating the potential beneficial effect of the use of computational tools in reducing AVF-related clinical problems, are needed.
- Conditions
- Kidney Failure, Chronic, Arteriovenous Fistulae
- Being tested
- AVF-simulation
- Keywords
- Arteriovenous fistulae (AVFs), Non-maturation, Computational simulation
- Medical subject headings
- Kidney Failure, Chronic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
AVF-simulationDevice
A mathematical computational tool, which is developed to calculate estimates for postoperative AVF hemodynamical changes in the upper extremity. The model is based on physical laws and calculations are carried out on patient-specific duplex measurements.
| Study group | Role | What they receive |
|---|---|---|
| Control | No intervention | Standard care in operative planning in AVF creation, that is physical examination and extensive duplex examination of the arm vasculature carried out by an experience vascular technician. |
| Simulation | Experimental | Standard care with the intervention of advisement of the preferred AVF-configuration, based on computational model simulation for predicting postoperative flow (AVF-simulation). Receives: Device: AVF-simulation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Occurence of non-maturation
Yes/No
A matured AVF has minimal flow of 500 mL/min and a minimal diameter of 4 mm by six weeks after AVF creation.
Measured: 6 weeks postoperatively
Secondary outcomes (5)
Occurence of high-flow complications
Yes/No
High flow complications considered are hemodialysis access induced distal ischemia (HAIDI) and heart failure. To classify for a high-flow complication, an AVF requires a flow reduction intervention within twelve weeks following creation. For this objective HAIDI and heart failure are not considered separately.
Measured: 6 weeks postoperatively
Primary patency rates
Intervention free period from AVF construction until an intervention is used to maintain or regain a patent vascular access.
Measured: 6 and 12 months
Agreement between predicted and measured flow (mL/min)
Correlation and/or Bland-Altman plot
Measured: up to 6 weeks
Usability of the computational tool
Qualitative assessment of the perceived benefit by surgeons in surgery planning via interviews. The interview will focus on terms of user-friendliness, reporting speed, reliability of predictions, etc.
Measured: 6 weeks
Functional AVF
AVF allows for cannulation with two needles and effective dialysis, with either dialysis blood flow >300mL/min without recirculation, or a measured kt/V ≥1.4 at the end of one of these sessions.
Measured: >6 weeks (when AVF is matured)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 May 2015 (estimated)
- Study startMay 2015
- Primary completionJul 2018
- Study completionJun 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Kidney Failure, ChronicStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 236 participants (actual)
Sponsor and investigators
- Lead sponsor
- Maastricht University Medical Center
- Sponsor type
- University, hospital or other
- Collaborators
- Maastricht University
- Responsible party
- Sponsor
- Investigators
- Niek Zonnebeld, MD, Principal investigator, Maastricht University Medical CenterJan Tordoir, MD, PhD, Principal investigator, Maastricht University Medical CenterWouter Huberts, PhD, Principal investigator, Maastricht University Medical CenterTammo Delhaas, MD, PhD, Principal investigator, Maastricht University Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02453412
- Sponsor's protocol ID
- NT12.01
- Other IDs
- NL51610.068.14
- Acronym
- 3S
- Status last verified
- Aug 2019
- First submitted
- 12 May 2015
- Last updated
- 22 Aug 2019
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- Undecided
Publications
Zonnebeld N, Huberts W, van Loon MM, Delhaas T, Tordoir JH. Preoperative computer simulation for planning of vascular access surgery in hemodialysis patients. J Vasc Access. 2017 Mar 6;18(Suppl. 1):118-124. doi: 10.5301/jva.5000661. Epub 2017 Mar 5.
PubMed 28297050
Study at a glance
From the registry record, last updated by the sponsor on 22 Aug 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Randomized-controlled Clinical Trial for the Evaluation of the Efficacy of Computational Simulation for the Planning of Vascular Access Surgery in Hemodialysis Patients
- ClinicalTrials.gov ID
- NCT02453412
- Acronym / sponsor ID
- 3S / NT12.01
- Conditions
- Kidney Failure, Chronic, Arteriovenous Fistulae
- Keywords
- Arteriovenous fistulae (AVFs), Non-maturation, Computational simulation
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 236 participants (actual)
- Lead sponsor
- Maastricht University Medical CenterUniversity, hospital or other
- Collaborators
- Maastricht University
- Study start
- May 2015 (actual)
- Primary completion
- Jul 2018 (actual)
- Study completion
- Jun 2019 (actual)
- First posted
- 25 May 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Patients suffering from end-stage renal disease (ESRD) are dependent on renal replacement therapy (dialysis). The majority of dialysis is facilitated by hemodialysis. For hemodialysis a vascular access is necessary, preferable an arteriovenous fistula (AVF) in which a vein is directly anastomosed to an artery. In order to use the AVF for hemodialysis three criteria have to be met; the minimal flow over the AVF is 600 mL/min, the diameter is at least 6 mm, and the AVF is located less than 6 mm under the skin. Unfortunately, approximately half of the patients (50%) are confronted with an AVF that does not meet these criteria; the so called non-maturation or primary failure. In case of non-maturation the AVF is not only unusable for dialysis, but also requires reinterventions on short- and long-term. Firstly to mature the AVF, and secondly, when the AVF is matured, to keep the vascular access. Using a computational simulation postoperative flow can be predicted. Based on patient-specific duplex measurements, the model can calculate the flow that can be expected following vascular access surgery for all AVF configurations; fore- or upper arm. These calculations lead to an advice which configuration is indicated; a flow that exceeds 600 mL/min, leading to maturation. Potentially the aforementioned 50% of non-maturation can be reduced. The patient then has an adequate vascular access and reinterventions are adverted, resulting in a decrease of costs, hospital demand, and an increase of the patients' quality of life. When the expected reduction of non-maturation is confirmed, the computational tool can be offered to other hospitals.
Detailed description
End-stage renal disease (ESRD) is a major and growing healthcare problem associated with substantial costs. By the end of 2010 the global patient population requiring chronic renal replacement therapy (RRT) exceeds 2 million, of which approximately 90% relies on hemodialysis (HD). The number of patients dependent on RRT are expected to annually increase with 8%. Based on this figure, it is expected that in 2030, 7.3 million ESRD patients need HD treatment. To facilitate adequate HD therapy a reliable vascular access (VA) is mandatory and can be provided by either creation of an autologous arteriovenous fistula (AVF), a prosthetic arteriovenous graft (AVG) or a central venous catheter (CVC). Guidelines by the National Kidney Foundation (NKF K/DOQI Guidelines), the Vascular Access Society (Good Nephrological Practice Guidelines) and the European Dialysis and Transplant Association (European Best Practice Guidelines on vascular access) advocate the implementation of an all-autologous fistula policy to maximize the use of AVF over AVG and CVC because AVF have the best long-term patency, fewer complications and require less interventions once fully maturated. Although the implementation of preoperative ultrasonography examination for vessel assessment has reduced the number of early AVF failure by improving the selection of the most suitable vessels and site for AVF creation, short- and long-term AVF dysfunction remains the major cause of morbidity and hospitalisation in HD patients, and is therefore the major limitation for HD treatment. This dysfunction is usually associated with non-maturation of the newly created AVF or the formation of neo-intimal hyperplasia (NIH) which potentially results in decreased access flow and eventual fistula thrombosis in up to 50% of AVFs. On the other hand, the low resistance vascular traject via the AVF may lead to impeded perfusion of the extremity distally of the AV anastomosis resulting in hand ischemia (HAIDI = Hemodialysis Access Induced Distal Ischemia), while an abundant AVF flow may lead to the development of left ventricular hypertrophy, both with potentially severe consequences. These high-flow complications occur in approximately 20% of fistulae. Numerous studies have investigated alternative preoperative mapping tools and criteria for reduction of AVF related complications. However, current clinical use of these individual tools and parameters does not take into account their potential interplay at a systemic level. Therefore one might consider that multiple prognostic parameters within a single patient are likely more valuable to improve outcome and therefore it is obvious to tailor the type of AVF to the individual patient. A possible solution to deal with multiple independent prognostic factors is implementation of a predictive patient-specific computational tool that relates geometrical, mechanical and hemodynamical parameters by means of physical laws. As a result, the computational tool takes the complex interplay between different prognostic parameters into consideration and accounts for individual differences in anatomy, physiology, demography and hemodynamics. Such an innovative computational tool opens new opportunities. By predicting postoperative flow abovementioned deleterious events can possibly be prevented. High-flow (>1500ml/min) and low-flow (<600ml/min) vascular access can then be predicted and consequently be rejected and a more suitable AVF-configuration chosen.
Consequently, simulation of outcome after AVF creation is at hand. Recently, the feasibility of VA computational simulation has been investigated and proven in the ARCH FP7 ICT-224390 project (ARCH; patient-specific image-based computational modeling for improvement of short- and long- term outcome of vascular access in patients on hemodialysis therapy). Within this technological and clinical study, longitudinal collection of cardiovascular data was performed with the intention to develop, calibrate and validate patient-specific modelling tools for surgical planning and assistance in the management of complications arising from AVF creation. Given the difficult and heterogeneous patient population, the study protocol was designed in such way that pre- and postoperative imaging could be performed strictly, aiming at complete datasets of structural, functional and demographical data. Although the computational simulation model has been validated in a small patient group, larger randomized observational patient studies, aiming at evaluating the potential beneficial effect of the use of computational tools in reducing AVF-related clinical problems, are needed.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Control | No intervention | –Standard care in operative planning in AVF creation, that is physical examination and extensive duplex examination of the arm vasculature carried out by an experience vascular technician. |
| Simulation | Experimental | Device: AVF-simulationStandard care with the intervention of advisement of the preferred AVF-configuration, based on computational model simulation for predicting postoperative flow (AVF-simulation). |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Incident patients that enter the pre-dialysis program because of end-stage renal failure and need for vascular access.
- Permanent dialysis patients in need of a new VA in the contralateral arm because of a previous failed access.
- Patients in which treatment of first choice is the creation of an autologous AVF.
- Patients with adequate arteries and veins (duplex) for creation of RC-, BC- or BBAVF.
- Patients that signed the written informed consent.
Key exclusion criteria (2 listed)
- Patients with contraindications for creation of an autologous AVF (skin infection, ischemia, heart failure)
- Patients with a previous vascular access in the ipsilateral arm.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| AVF-simulationA mathematical computational tool, which is developed to calculate estimates for postoperative AVF hemodynamical changes in the upper extremity. The model is based on physical laws and calculations are carried out on patient-specific duplex measurements. | Device | Simulation |
Primary outcome
Occurence of non-maturation
Time frame: 6 weeks postoperatively
Yes/No A matured AVF has minimal flow of 500 mL/min and a minimal diameter of 4 mm by six weeks after AVF creation.
5 secondary outcomes
Occurence of high-flow complications
Time frame: 6 weeks postoperatively
Primary patency rates
Time frame: 6 and 12 months
Agreement between predicted and measured flow (mL/min)
Time frame: up to 6 weeks
Usability of the computational tool
Time frame: 6 weeks
Functional AVF
Time frame: >6 weeks (when AVF is matured)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Aug 2019.
- Derived from this study: PubMed 28297050Zonnebeld N, Huberts W, van Loon MM, Delhaas T, Tordoir JH. Preoperative computer simulation for planning of vascular access surgery in hemodialysis patients. J Vasc Access. 2017 Mar 6;18(Suppl. 1):118-124. doi: 10.5301/jva.5000661. Epub 2017 Mar 5.
- Individual participant dataSharing planned: Undecided
Related trials for Kidney Failure, Chronic
Recruiting
Diuretic Tuner Clinical Decision Support
Edema, Hypervolemia
RecruitingObservational study
Immune System Related Kidney Disease
Kidney Disease, Nephrotic Syndrome
Recruiting
Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) in Chronic Kidney Disease (CKD)
Chronic Kidney Diseases
RecruitingPhase 4
Empagliflozin in Heart Failure With Reduced Ejection Fraction and End Stage Renal Disease
Heart Failure With Reduced Ejection Fraction, End Stage Renal Disease on Dialysis
Enrolling by invitationObservational study
AK+ Guard™ Pilot Study in Chronic Kidney Disease: Outpatient Diagnostic Accuracy and Remote Monitoring
Hyperkalemia, Chronic Kidney Disease (Stage 3-4)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Niek Zonnebeld, MD principal investigator
Maastricht University Medical Center
Jan Tordoir, MD, PhD principal investigator
Maastricht University Medical Center
Wouter Huberts, PhD principal investigator
Maastricht University Medical Center
9 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing AVF-simulation in people with Kidney Failure, Chronic and Arteriovenous Fistulae, run by Maastricht University Medical Center at 9 sites in Netherlands.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 22 Aug 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 9 sites in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Occurence of non-maturation (time frame: 6 weeks postoperatively). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02453412, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Aug 2019.